Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02761538
Other study ID # UF 9534
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 17, 2015
Est. completion date December 2019

Study information

Verified date February 2019
Source University Hospital, Montpellier
Contact Antoine AA AVIGNON, PU-PH
Phone +33(0)467 33 84 02
Email a-avignon@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators developed the Aviitam® online platform. The purpose of the project is to test the medico-economic impact related to the utilization of the Aviitam online platform in primary care.

Primary objective: To assess the cost-effectiveness at 24 months follow-up of the utilization of the Aviitam® online software in primary care for people with obesity and at least one comorbidity compared to a usual follow-up in primary care.

Secondary objectives: Weight loss; quality of life ; blood pressure change; changes in lipid profile, blood glucose and HbA1c; physician satisfaction; patients satisfaction, profiling of patients and data mining analysis on the collected data.

Method : Overweight & obese patients with associated comorbidities will receive a 24 months follow-up to assess the impact of the use of the online platform Aviitam®.

Practitioners will be randomized by lot between an Aviitam® group and a control group (usual care).

A medico-economic analysis will be conducted with a cost-effectiveness analysis and a budget impact analysis.

With no hypothesis on the primary endpoint, the calculation of the required number of subjects was based on the quality of life. 150 patients will be included per group Patients of the 2 groups will be assessed at baseline and after 24 months. The first day of each month, each patient included in the study will receive a questionnaire to fill online to evaluate their health care consumption in the previous month and the EQ5D questionnaire , a standardized questionnaire validated in French to assess the effects on health and to be used to calculate cost - utility.

Expected results and perspectives Proving the effectiveness of the Aviitam® online program focused on non-drug therapies and therapeutic lifestyle changes for overweight and obesity management with reduced health costs, improvement in quality of life, reduction in weight and improvement of comorbidities.

In terms of public health, the use of the platform Aviitam® can be expect to improve management of excess body weight and reduced health costs. Furthermore, Aviitam® could be a valuable tool to support healthcare professionals in outpatient therapeutic education approaches.


Description:

Method : Overweight & obese patients with associated comorbidities (hypertension, prediabetes, type 2 diabetes, dyslipidemia, sleep disorders, past history of CVDs > 6 months, stable CVD, peripheral arterial disease) will receive a 24 months follow-up to assess the impact of the use of the online platform AviitamĀ®.

Practitioners will be randomized by lot between an AviitamĀ® group and a control group (usual care).

A medico-economic analysis will be conducted with a cost-effectiveness analysis and a budget impact analysis.

With no hypothesis on the primary endpoint, the calculation of the required number of subjects was based on the quality of life. 150 patients will be included per group, for a total of 300 patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria:Man or woman aged 35-65 years Having signed an informed written consent Being affiliated to social security

With a BMI between 25 and 45 kg / m2 and at least one of the following criteria associated:

- A known hypertension treated or not

- A known prediabetes [fasting glucose between 110 and 126 mg / l or metabolic syndrome as defined in the 2009 consensus of the International Diabetes Federation and the American heart Association.

- A known type 2 diabetes, treated or not

- A known dyslipidemia treated or not

- A known sleep disorder

- A known history of cardiovascular disease> 6 months, a stable known cardiovascular disease, peripheral arterial disease.

Exclusion Criteria:

- No Having signed an informed written consent

- No Being affiliated to social security

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
AVIITAM
The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.

Locations

Country Name City State
France Departement Nutrition Diabète Hôpital lapeyronie 371 avenue du Doyen Gaston Giraud Montpellier
France Montpellier University Hospital Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Weight loss Weight loss expressed in kg 24 months follow-up
Primary "Quality of life" (scale) Variation of scale in quality of life "Quality of life assessed by Health-Related Quality of Life (HRQOL) between M0 and M24 24 months follow-up
Secondary Systolic blood pressure (mmHg) Variation of resting systolic blood between M0 and M24 24 months
Secondary Diastolic blood pressure (mmHg) Variation of resting diastolic blood betwenn M0 and M24. 24 months
Secondary Blood LDL Cholesterol (mmol/l) . Variation of fasting LDL-cholesterol levels (mmol/l) between M0 and M24 24 months
Secondary Blood HDL Cholesterol (mmol/l) Variation of fasting HDL Cholesterol levels (mmol/l) between M0 and M24. 24 months
Secondary Blood Triglycerides (mmol/l) Variation of fasting Triglycerides levels (mmol/l) between M0 and M24 24 months
Secondary Blood glucose (mmol/l) Variation of fasting blood glucose levels (mmol/l) between M0 and M24 24 months
Secondary HbAlc blood Variation of HbAlc (mmol/mol) between M0 and M24 24 months
See also
  Status Clinical Trial Phase
Terminated NCT02191501 - Endoscopic Suturing of the Gastric Pylorus to Delay Gastric Emptying and Treat Obesity N/A
Completed NCT01519583 - WalkMore Walking Interventions for Overweight/Obese Postmenopausal Women N/A
Completed NCT01358890 - Low-Carbohydrate Diet Intervention on Body Weight Phase 2/Phase 3
Recruiting NCT02036996 - Evaluation of EarlySense; a Contact-less Heart and Respiration Rate Monitoring in Sleep Lap Examined N/A
Not yet recruiting NCT01753609 - Safety and Performance Evaluation of Tulip Device in Healthy Overweight and Obese Volunteers N/A